News

ISAR Life Sciences has secured additional funding from private investors, including private equity, to support portfolio development and preparation for European market entry. The company continues to evaluate late-stage assets in oncology, cardio-metabolic, and immunology.

The company is engaging with manufacturers, CROs, and regional distributors to advance market entry initiatives in DACH, with planned expansion across Europe and Asia.